Peptable

Comparison

Sermorelin vs Thymosin Beta-4

Function

While Sermorelin is used as a diagnostic agent for assessing GH secretory capacity and as a research tool or off-label therapy to increase endogenous GH in GH-deficient or age-related contexts1727, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.

Mechanism

While Sermorelin works as a synthetic 29-amino-acid peptide identical to the 1–29 N-terminal fragment of human GHRH that stimulates GH synthesis and secretion by binding pituitary GHRH receptors1727120, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.

Receptor

Sermorelin

Growth hormone–releasing hormone receptor (GHRHR) on pituitary somatotrophs94103120

Thymosin Beta-4

Binds actin monomers (G-actin) at both barbed and pointed ends to sterically block polymerization55

Organism or Origin

Sermorelin

Synthetic peptide corresponding to human hypothalamic GHRH(1–29) 17120

Thymosin Beta-4

Human and other mammals (ubiquitous cytosolic peptide) 7988

Gene

Sermorelin

GHRH

Thymosin Beta-4

TMSB4X

Summary

Sermorelin and Thymosin Beta-4 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Sermorelin is more often discussed in the realm of Metabolic and endocrine and Aging and longevity, whereas Thymosin Beta-4 is more often associated with the realm of Musculoskeletal health, Cardiovascular health, and Dermatology and aesthetics. Their biological logic is quite different: Sermorelin is a receptor agonist, whereas Thymosin Beta-4 is a signaling modulator and a protein interaction inhibitor. Sermorelin has a more synthetic analog origin, while Thymosin Beta-4 is closer to natural endogenous background and their development context also differs, with Sermorelin approved while Thymosin Beta-4 is in Clinical phase 2. Sermorelin carries amidation features, while Thymosin Beta-4 instead reflects acetylation changes, while their sequence patterns also diverge, with Sermorelin showing alpha-helical domain features and Thymosin Beta-4 showing protein-mimetic sequence features.

Sources

17Sermorelin - Wikipedia, https://en.wikipedia.org/wiki/Sermorelin
27Sermorelin, https://pubchem.ncbi.nlm.nih.gov/compound/Sermorelin
94Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth-hormone-releasing_hormone_receptor
103Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone_releasing_hormone_receptor
120Growth hormone–releasing hormone - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone%E2%80%93releasing_hormone
2TB-500 (Thymosin Beta-4) | Peptide Biologix, https://peptidebiologix.com/tb-500
12Thymosin Beta-4 vs TB-500 | What to Know in 2024, https://www.peptidesciences.com/peptide-research/thymosin-beta-4-vs-tb-500
79TMSB4X Gene: Function, Research, and Clinical Applications, https://learn.mapmygenome.in/genemap/tmsb4x
88TMSB4X thymosin beta 4, X-linked FX PTMB4 TB4X TMSB4, https://www.sigmaaldrich.com/DE/en/genes/tmsb4x